Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4140452 | 0.80 | CYP1A2 (0.48) | KDM4EBCHEACHE | |
| SCHEMBL1932770 | 0.79 | KDM4E (0.43) | KDM4E | |
| SCHEMBL29796521 | 0.79 | KDM4E (0.43) | KDM4E | |
| SCHEMBL9980511 | 0.79 | KDM4E (0.40) | KDM4E | |
| SCHEMBL14999905 | 0.79 | KDM4E (0.40) | KDM4E | |
| SCHEMBL30380008 | 0.79 | KDM4E (0.40) | KDM4EBCHE | |
| SCHEMBL12458108 | 0.75 | KDM4E (0.37) | KDM4EBCHEACHE | |
| SCHEMBL9696186 | 0.73 | MGAM (0.53) | KDM4E | |
| SCHEMBL29364156 | 0.73 | ALDH1A1 (0.41) | KDM4E | |
| SCHEMBL247478 | 0.73 | ALDH1A1 (0.41) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116134026-A | Triazole derivatives and their use as tankyrase inhibitors | 奥斯陆大学国家医院 | 2023-05-16 | — | — | CN | disclosed |
| EP-2991992-B1 | QUINOLONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-07-25 | — | — | EP | disclosed |
| US-9540399-B2 | Quinolone derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2017-01-10 | — | — | US | disclosed |
| EP-2991992-A1 | QUINOLONE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2016-03-09 | — | — | EP | disclosed |
| US-20160060276-A1 | QUINOLONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-03-03 | — | — | US | disclosed |
| WO-2014178008-A1 | QUINOLONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-11-06 | — | — | WO | disclosed |
| EP-2022793-B1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2014-06-04 | — | — | EP | disclosed |
| US-8367831-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8367831-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| US-8211908-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-8211908-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-2022793-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060276-A1 | QUINOLONE DERIVATIVES | NQO2, QARS1, RECQL | KDM4E 2055/4885BCHE 3574/4885ACHE 2202/4885 |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | IKZF3, ZC3HAV1L, H1-4 | KDM4E 1732/4885BCHE 2910/4885ACHE 3253/4885 |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | IKZF3, ZC3HAV1L, CXXC5 | KDM4E 1786/4885BCHE 3113/4885ACHE 3402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.